Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
11 |
Material Type: Artigo
|
![]() |
Are anti-HER2 agents the best choice in metastatic breast cancer with an HER2 positive switch from primary tumour? A retrospective multi institution analysis of clinical-pathological characteristics and outcomesBertolini, I ; Diodati, L ; Fontana, A ; De Angelis, C ; Cantini, L ; Cecconi, S ; Montagnani, I ; Salvadori, B ; Ferrarini, I ; Ferrari, P ; Michelotti, A ; Landucci, E ; Fanelli, G ; Scatena, C ; Naccarato, A G ; Berardi, R ; Pistelli, M ; Falcone, AAnnals of oncology, 2017-10, Vol.28 Suppl 6, p.vi42-vi43 [Periódico revisado por pares]EnglandTexto completo disponível |
12 |
Material Type: Artigo
|
![]() |
Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology DepartmentsMeattini, I ; Salvadori, B ; Coltelli, L ; Perna, M ; Carta, G A ; Becherini, C ; Grassi, R ; Garlatti, P ; Cappelli, S ; Desideri, I ; Vannini, A ; Fontana, A ; Landucci, E ; Michelotti, A ; Ricci, S ; Allegrini, G ; Falcone, A ; Livi, LAnnals of oncology, 2017-10, Vol.28 Suppl 6, p.vi42 [Periódico revisado por pares]EnglandTexto completo disponível |
13 |
Material Type: Artigo
|
![]() |
Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational studyD' Alonzo, A. ; Bighin, C. ; Puglisi, F. ; Gerratana, L. ; De Laurentis, M. ; Fontana, A. ; Pugliese, P. ; Ferzi, A. ; Montemurro, F. ; Arpino, G. ; Poggio, F. ; Vaglica, M. ; Dellepiane, C. ; Blondeaux, E. ; Benedetta, C. ; Cognetti, F. ; Garrone, O. ; Turletti, A. ; Pastorino, S. ; Del Mastro, L.Annals of oncology, 2017-10, Vol.28, p.vi25-vi25 [Periódico revisado por pares]England: Elsevier LtdTexto completo disponível |
14 |
Material Type: Artigo
|
![]() |
Alcohol consumption and risk of Hodgkin's lymphoma and multiple myeloma: a multicentre case–control studyGorini, G. ; Stagnaro, E. ; Fontana, V. ; Miligi, L. ; Ramazzotti, V. ; Amadori, D. ; Rodella, S. ; Tumino, R. ; Crosignani, P. ; Vindigni, C. ; Fontana, A. ; Vineis, P. ; Seniori Costantini, A.Annals of oncology, 2007-01, Vol.18 (1), p.143-148 [Periódico revisado por pares]Oxford: Elsevier LtdTexto completo disponível |
15 |
Material Type: Artigo
|
![]() |
270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohortCucciniello, L. ; Blondeaux, E. ; Bighin, C. ; Gasparro, M.S. ; Russo, S. ; Dri, A. ; Pugliese, P. ; Fontana, A. ; Naso, G. ; Ferzi, A. ; Riccardi, F. ; Sini, V. ; Fabi, A. ; Montemurro, F. ; De Laurentiis, M. ; Arpino, G. ; Del Mastro, L. ; Gerratana, L. ; Puglisi, F.Annals of oncology, 2022-09, Vol.33, p.S661 [Periódico revisado por pares]Texto completo disponível |
16 |
Material Type: Artigo
|
![]() |
101P Accuracy of detecting PIK3CA mutations on circulating tumour (ct) DNA as compared to tumour tissue (TT) in breast cancer (BC) patients (pts): Results from a systematic review and meta-analysisDe Angelis, C. ; Bruzzone, M. ; Caparica, R. ; Crucitta, S. ; Ceppi, M. ; Fontana, A. ; Falcone, A. ; Prat, A. ; de Azambuja, E. ; Lambertini, M.Annals of oncology, 2020-09, Vol.31, p.S281-S282 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
17 |
Material Type: Artigo
|
![]() |
1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patientsDel Re, M. ; Lorenzini, G. ; Cucchiara, F. ; De Angelis, C. ; Crucitta, S. ; Diodati, L. ; Cavallero, D. ; Bargagna, I. ; Cinacchi, P. ; Fratini, B. ; Salvadori, B. ; Fontana, A. ; Danesi, R.Annals of oncology, 2020-09, Vol.31, p.S1093-S1093 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
18 |
Material Type: Artigo
|
![]() |
239P Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patientsDel Re, M. ; Omarini, C. ; Diodati, L. ; Palleschi, M. ; Meattini, I. ; Crucitta, S. ; Isca, C. ; Fogli, S. ; Bleve, S. ; Lorenzini, G. ; Fontana, A. ; Livi, L. ; Piacentini, F. ; De Giorgi, U. ; Danesi, R.Annals of oncology, 2021-09, Vol.32, p.S463-S464 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
19 |
Material Type: Artigo
|
![]() |
LBA19 - Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)Untch, M. ; Geyer, C.E. ; Huang, C. ; Loibl, S. ; Wolmark, N. ; Mano, M.S. ; von Minckwitz, G. ; Brufsky, A. ; Pivot, X. ; Polikoff, J. ; Fontana, A. ; Kaufman, B. ; Alcedo, J.C. ; Boulet, T. ; Liu, H. ; Song, C. ; Mamounas, E.P.Annals of oncology, 2019-10, Vol.30, p.v854-v855 [Periódico revisado por pares]Elsevier LtdTexto completo disponível |
20 |
Material Type: Artigo
|
![]() |
Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centreSbrana, A. ; Paolieri, F. ; Sammarco, E. ; Bloise, F. ; Zucchelli, G. ; Massa, V. ; Lorenzini, G. ; Borelli, B. ; Boccaccino, A. ; Catanese, S. ; Pecora, I. ; Galli, L. ; Fontana, A. ; Falcone, A. ; Antonuzzo, A.Annals of oncology, 2019-10, Vol.30, p.v720 [Periódico revisado por pares]Texto completo disponível |